Table 2 Examples of ALK translocations, chromosomal locations, and relative frequencies in solid and hematologic malignancies.

From: ALK fusions in the pan-cancer setting: another tumor-agnostic target?

ALK partners

Tumor type comment

Chromosomal alterations

ALK fusion approximate frequency

(%) in tumor

References

 

Solid Tumors

   

ATIC

IMT

inv (2) (p23q35)

50–55% of all IMT

44

A2M

IMT

t (2;12) (p23; p13)

 

45

CLTC

IMT

t (2;17) (p23; q23)

 

16

RANBP2

IMT

inv (2) (p23q11-13)

 

16,66

TPM3 and TPM4

IMT

t(1;2) (q21;p23) and t(2;19)(p23;p13)

 

46

PPFIBP1

IMT

t (2;12) (p23; p11)

 

16

SQSTM1

NSCLC

t (2;5) (p23.1; q35.3)

3–7% of all NSCLC

16

CLTC

NSCLC

t (2;17) (p23; q23)

 

2

HIP1

NSCLC

t (2;7) (p23; q11.23)

 

2,16

DCTN1

NSCLC

inv (2) (p13p23)

 

2

A2M

NSCLC

t (2;12) (p23; p13)

 

16

TPR

NSCLC

t (1;2) (q31.1; p23)

 

16

EML4

NSCLC

Most common ALK partner in NSCLC

inv (2) (p21p23)

 

20

KIF5B

NSCLC

t (2;10) (p23; p11)

 

2,16

SPTBN1

CRC

t (2) (p16.2; p23)

<1% of all CRC

47

CAD

CRC

inv (2) (p23; p22)

 

48

EML4

CRC

inv (2) (p21p23)

 

58

STRN

CRC

t (2) (p23; p22.2)

 

49

VCL

RCC

t (2;10) (p23; q22)

<1% of all RCC

16

STRN

RCC

t (2) (p23; p22.2)

 

50

TPM3

RCC

t (1;2) (q21; p23)

 

16

EML4

RCC

inv (2) (p21p23)

 

16

DCTN1

PDAC

inv (2) (p13p23)

N/A

64

STRN

CCA

t (2) (p23; p22.2)

N/A

51

EML4

BC

inv (2) (p21p23)

N/A

52

TPM4

ESCC

t (2;19) (p23; p13)

N/A

53

FN1

OC

inv (2) (p23q34)

N/A

57

STRN

MPM

t (2) (p23; p22.2)

N/A

54

STRN

TC

t (2) (p23; p22.2)

<1% of all TC

55

DCTN1

TC

inv (2) (p13p23)

 

16

FN1

LMS

inv (2) (p23q34)

N/A

56

 

Hematological malignancies

   

TFG

ALCL

t (2;3) (p23; q21)

 

59

RNF213/ALO17

ALCL

t (2;17) (p23; q25)

 

16

NPM1

ALCL

t (2;5) (p23; q35)

~80% of pediatric and ~50% of adult ALCL harbor NPM1-ALK

7,16

CLTC

ALCL

t (2;17) (p23; q23)

 

60

MSN

ALCL

t (2; X) (p32; q11-12)

 

16

TPM3

ALCL

t (1;2) (q25; p23)

 

16

TPM4

ALCL

t (2;19) (p23; p13)

 

16

EML4

DLBCL

inv (2) (p23; q21)

<1% of all DLBCL

61

SEC31A

DLBCL

t (2;4) (p24; q21)

 

62

CLTC

DLBCL

t (2;17) (p23; q23)

 

65

RANBP2

AML

Inv (2) (p23; q13)

N/A

63

KIF5B

Histiocytosis

t (2;10) (p23; p11)

N/A

2

  1. Abbreviations: A2M α-2-macroglobulin, ALCL anaplastic large cell lymphoma, AML acute myeloid leukemia, ATIC 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase, BC breast cancer, CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase, CRC colorectal cancer, CCA cholangiocarcinoma, CLTC clathrin heavy chain, DCTN1 dynactin, DLBCL diffuse large B cell lymphoma, EML4 echinoderm microtubule-associated protein like-4, ESCC esophageal squamous cell carcinoma, FN1 fibronectin 1, HIP1 huntingtin-interacting protein 1, IMT inflammatory myofibroblastic tumor, KIF5B kinesin family member 5B, LMS leiomyosarcoma, MPM malignant peritoneal mesothelioma, MSN moesin, NA not available, NPM1 nucleophosmin1, NSCLC non-small cell lung cancer, OC ovarian carcinoma, PDAC pancreatic ductal carcinoma, PPP1CB PP1-beta-catalytic subunit, RANBP2 RAN binding protein 2, RCC renal cell carcinoma, RNF213 ring finger protein 213, SEC31A SEC31 homolog A, SPTBN1 spectrin beta non-erythrocytic 1, SQSTM1 sequestosome 1, STRN striatin, TC thyroid carcinoma, TFG TRK-fused gene, TPM3 tropomyosin 3, TPM4 tropomyosin 4, TPR translocated promoter region, VCL vinculin.
Back to article page